News
The company also encounters competitive risks from other organizations developing therapies for chronic kidney disease.
ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company ...
ProKidney Corp. (PROK) shares just saw a massive green day. Results from Phase 2 were compelling and the data sharply ...
ProKidney shares are trading sharply higher Wednesday morning. The stock is gaining following a marked surge on Tuesday ...
2h
Zacks Investment Research on MSNPROK Surges More Than 500% on Upbeat Data From Kidney Cell Therapy StudyShares of ProKidney Corp. PROK skyrocketed 515% yesterday after the company reported encouraging top-line data from the phase ...
ProKidney’s stock was the biggest gainer and most actively traded on Tuesday following “very intriguing” news regarding the ...
6h
InvestorsHub on MSNProKidney Shares Soar After Citi Lifts Price Target to $9Shares of ProKidney Corp. (NASDAQ:PROK) jumped 65% in pre-market trading Wednesday, extending the dramatic rally seen on ...
ProKidney shares surged 500% on positive Phase 2 CKD results. Read why I remain cautious about PROK stock despite the recent ...
ProKidney shares soar on promising Rilparencel mid-stage data for chronic kidney disease. But PROK stock remains a high-risk ...
ProKidney (NASDAQ: PROK) experienced a surge of 515% during Tuesday's trading session and gained additional 8.58% after-hours ...
Live Updates Live Coverage Updates appear automatically as they are published. Nvidia Crosses $4 Trillion Market Cap 10:50 am ...
At one point, ProKidney had been running an international phase 3 trial, dubbed PROACT 2, of rilparencel alongside the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results